18
项与 Dendritic cell vaccine(Shenzhen Geno-Immune Medical Institute) 相关的临床试验Safety and Feasibility Study of Dendritic Cell (DC) Vaccination Expressing WT1/hTERT/Survivin in AML Patients With Minimal Residual Disease (MRD)
The primary aim of this innovative immunotherapy using WT1/hTERT/Survivin-loaded DCs is to determine whether this novel DC vaccination is safe and can significantly prevent clinical relapse and increase survival of acute myeloid leukemia (AML) patients by eradicating minimal residual disease, while maintaining its safety profile in this phase I trial.
Safety and efficacy evaluation of DC vaccine monotherapy / DC vaccine combined with PD1 inhibitor in metastatic clear cell renal cell carcinoma
Phase I/II Study of DC Vaccine Targeting MG-7 Antigen to Treat Gastric Cancer
The primary purpose of the study is to determine the safety and efficacy of autologous DC vaccine in patients with later stage of gastric cancer. The DC vaccine is gene modified with gastric cancer specific antigen MG-7.
100 项与 Dendritic cell vaccine(Shenzhen Geno-Immune Medical Institute) 相关的临床结果
100 项与 Dendritic cell vaccine(Shenzhen Geno-Immune Medical Institute) 相关的转化医学
100 项与 Dendritic cell vaccine(Shenzhen Geno-Immune Medical Institute) 相关的专利(医药)
1
项与 Dendritic cell vaccine(Shenzhen Geno-Immune Medical Institute) 相关的文献(医药)2001-04-01·Drug Discovery Today2区 · 医学
Dendritic vaccine promising for gliomas
2区 · 医学
Article
作者: Lawrence, Rebecca
100 项与 Dendritic cell vaccine(Shenzhen Geno-Immune Medical Institute) 相关的药物交易